Skip to main content
Download PDF

Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy

Molecular Cancer volume 22, Article number: 175 (2023) Cite this article

The Original Article was published on 24 June 2014

Correction: Mol Cancer 13, 157 (2014)

https://doi.org/10.1186/1476-4598-13-157

Following publication of the original article [1], a reader reported that “two signals in Fig. 3C seem to be unexpectedly similar”, and as original blots are no longer available (only cropped versions of the triplicate blots), an alternative replicate of the Fig. 3c blot is provided in this correction. This replacement does not alter the results presented in the text. The correct figure is given below.

Fig. 3
figure 1

mTOR and eEF2k mediated regulation of eEF2 phosphorylation. A Immunoblot analysis of total and phosphorylated mTOR(Ser2448) in SKBR3-par and SKBR3-L cells following 24 h. lapatinib treatment. B Effect of rapamycin on growth of SKBR3-par and SKBR3-L cells. Error bars represent the mean ± SD (n = 3). C Immunoblot analysis of total and phosphorylated eEF2(Thr56) following 24 h. treatment with lapatinib and/or rapamycin. D Immunoblot analysis of total and phosphorylated eEF2k(Ser366, 359) in SKBR3-par and SKBR3-L cells following 24 h. lapatinib treatment. E Immunoblot examining the effect of NH125 alone and in combination with lapatinib on the phosphorylation of eEF2(Thr56) in SKBR3-par cells. *denotes p ≤ 0.05

Full size image

Reference

  1. McDermott MSJ, Browne BC, Conlon NT, et al. PP2A inhibition overcomes acquired resistance to HER2 targeted therapy. Mol Cancer. 2014;13:157. https://doi.org/10.1186/1476-4598-13-157.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland

    Martina S. J. McDermott, Neil T. Conlon, Michael Henry, Paula Meleady, Martin Clynes, Paul Dowling, John Crown & Norma O’Donovan

  2. Cancer Research Program, The Kinghorn Cancer Centre, Garvan Institute of Medical Research Sydney, Sydney, NSW, Australia

    Brigid C. Browne

  3. Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA

    Neil A. O’Brien & Dennis J. Slamon

  4. Department of Biology, National University of Ireland, Maynooth, Maynooth, Co, Kildare, Ireland

    Paul Dowling

  5. Department of Medical Oncology, St Vincent’s University Hospital, Elm Park, Dublin 4, Ireland

    John Crown

Authors
  1. Martina S. J. McDermott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brigid C. Browne
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neil T. Conlon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Neil A. O’Brien
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dennis J. Slamon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael Henry
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paula Meleady
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Martin Clynes
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Paul Dowling
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. John Crown
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Norma O’Donovan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Norma O’Donovan.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McDermott, M.S.J., Browne, B.C., Conlon, N.T. et al. Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy. Mol Cancer 22, 175 (2023). https://doi.org/10.1186/s12943-023-01890-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12943-023-01890-z

Molecular Cancer

ISSN: 1476-4598